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In this issue, Nishio et al report the results of 
the multicentre phase II trial with nivolumab 
checkpoint inhibitor (CPI) immunotherapy 
in Japanese patients with advanced or recur-
rent non-squamous non-small cell lung 
cancer (NSCLC), who progressed after plat-
inum-containing chemotherapy.1
Over the last 5 years, CPI therapy has revo-
lutionised the treatment of advanced NSCLC. 
Several international phase III randomised 
trials compared CPI therapy with docetaxel 
chemotherapy in patients with relapsed 
NSCLC. Based on the results of these trials, 
nivolumab was approved in this setting by 
the European Medicines Agency (EMA) 
and the US Food and Drug Administration 
(FDA),2 3 pembrolizumab was approved in 
programmed cell death 1 ligand (PD-L1) 
expressing tumours by EMA and FDA4 and 
atezolizumab was recently approved by FDA, 
while EMA approval is pending.5 In that 
respect, the data of Nishio et al are not ground-
breaking. They are of interest, however, as 
several globally established treatments for 
NSCLC have proved to have a different imple-
mentation in Japanese population. There are 
several examples underpinning this finding.
The first example is the comparator 
regimen in the phase III studies on CPI 
therapy in relapsed NSCLC, docetaxel 
chemotherapy. Based on several phase II 
and phase III studies, a significantly higher 
risk for grade 3/4 neutropenia (OR 19, 95% 
CI 3.6 to 99) was noted in South-East Asian 
patients who were on docetaxel once every 
3 weeks.6 Based on this finding, the stan-
dard dose for docetaxel in Japanese patients 
is 60 mg/m2, compared with 75 mg/m2 in 
Caucasian patients. Another example is the 
transpacific analysis of carboplatin–pacli-
taxel, a commonly used regimen in patients 
with NSCLC.7 A prospective pharmacogenetic 
comparison of the biopsy samples of carbo-
platin–paclitaxel treated patients was made 
in one US phase III trial8 and two Japanese 
phase III trials.9 10 Clinical results were similar 
in the two Japanese trials, but significantly 
different in the US trial, both for survival and 
haematological toxicity. Several genotypic 
differences in paclitaxel disposition or DNA 
repair between the two ethnic groups were 
documented as a probable explanation for 
clinical outcome differences. Similar data 
have been reported with irinotecan-based 
regimens when comparing the phase III data 
from the US SWOG 0124 study11 with those 
from the Japanese JCOG 9511 study.12 In a 
common-arm cross-trial analysis, significant 
differences in objective response rate (ORR), 
overall survival (OS) and toxicity were noted 
between the two trials.13
In the setting of tyrosine kinase inhibitor 
(TKI) therapy, remarkable differences were 
noted in efficacy and safety. In a comparison 
between US and South-Korean patients with 
NSCLC, the South-East Asian ethnicity was 
a favourable prognostic factor overall, and 
a clearly greater survival benefit was noted 
in the epidermal growth factor receptor 
(EGFR)-TKI era for Korean patients.14 In 
a global review of interstitial lung disease 
(ILD) caused by gefitinib or erlotinib in 
advanced NSCLC, the overall incidence of 
ILD events was 1.2%.15 In contrast, ILD was 
quite common in a prospective Japanese 
cohort study.16 The incidence of an ILD event 
in Japanese patients on gefitinib therapy was 
4.5 per 1000 person-weeks. Likewise, in a 
retrospective study, the incidence of ILD was 
5.4%.17
The study of Nishio et al is an opportunity 
to judge nivolumab in an exclusively Japanese 
cohort,1 and to compare the findings with 
more global datasets. As Nishio et al included 
only patients with non-squamous NSCLC, by 
far the most common histology in Japan, the 
most appropriate comparison is the one with 
the Checkmate 057 study.3 In the latter, only 
3% of the patients were of Asian ethnicity. 
With the caveat of the smaller number of 
patients in the Japanese study, the efficacy 
data seem to be rather comparable (table 1). 
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In the Japanese study, there were 27.6% never-smokers 
and 26.3% of patients with EGFR-mutated tumours. 
In that respect, the ORR of 22% is at least as good as 
in Western population, as never-smokers and patients 
with EGFR-mutated tumours are in general—and in this 
Japanese study as well—less optimal candidates for CPI 
therapy. The most remarkable difference is the better OS 
outcome in the Japanese patients, but that probably also 
is the result of the important proportion of patients with 
EGFR-mutated tumours, who survive longer when appro-
priately treated with TKIs.18 As for toxicity, however, the 
data suggest that Japanese patients may be more vulner-
able to side effects of CPI, especially as 16% of the patients 
were discontinued from CPI therapy, a figure clearly 
higher than in most western studies. Again, there is the 
caveat of low numbers, and the possibility that a learning 
curve on how to deal with these toxicities may explain 
the results. Remarkable, and of potential concern, is the 
higher incidence of all grade and grade 3–4 immune-re-
lated pneumonitis in the JapicCTI-132073 study.
PD-L1 expression is a biomarker for CPI immuno-
therapy. In Checkmate 057, there was no benefit in OS 
for nivolumab compared with docetaxel in patients 
with a tumour with PD-L1 expression of <10% (HR for 
OS was 1.00).3 Moreover, in the OS curve, patients on 
nivolumab initially did worse, then there was a cross-over, 
and in the long run patients on nivolumab did better. The 
test method in the Japanese data was the same as in the 
Checkmate 057 study (automated immunohistochem-
ical assay on Dako platform with the rabbit anti-human 
PD-L1 antibody clone 28–8). We should, however, be very 
careful in the interpretation of the PD-L1 expression data 
in the Japanese phase II trial with only 76 patients, as the 
different PD-L1 expression groups become very small 
there, but overall the same trend of PD-L1 acting as a 
positive predictive biomarker seems to be in place (table 
2).
As a whole, the results of Nishio et al are reassuring 
that CPI therapy with nivolumab is just as worthwhile in 
Japanese patients with relapsed non-squamous NSCLC. 
Factors of particular interest in their population are the 
relationship between CPI therapy effects in EGFR-mutated 
and wild-type tumours, and the potential differences in 
toxicity patterns, especially in immune-related pneumo-
nitis. Based on this series, these factors deserve special 
attention in future larger Japanese clinical trials.
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